Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
During COVID-19 the switch to a virtual learning platform changed the way in which students digested content from their education. Now that the pandemic has slowed, the question of the need for online ...
NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research ...
Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results